Minister J.P. Nadda holds bilateral meeting with Helen Clark, Board Chair of the Partnership for Maternal, Newborn and Child Health in Geneva
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The development comes as stroke remains one of the world’s biggest health threats
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company reported free cash flow of Rs. 2,590 Mn for FY26
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Access to genomic testing, not therapy cost, is the biggest challenge
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Subscribe To Our Newsletter & Stay Updated
